STEVE ASELAGE - 05 Nov 2021 Form 4 Insider Report for Travere Therapeutics, Inc. (TVTX)

Role: Director
Signature: /s/ Elizabeth E. Reed, Attorney-in-Fact
Issuer symbol: TVTX
Transactions as of: 05 Nov 2021
Net transactions value: -$100,000
Form type: 4
Filing time: 09 Nov 2021, 15:05:36 UTC
Previous filing: 03 Nov 2021
Next filing: 18 Nov 2021
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TVTX	Common Stock	Options Exercise	$162,300	+10,000	+6.2%	$16.23	171,794	05 Nov 2021	Direct
transaction	TVTX	Common Stock	Sale	$262,300	-10,000	-5.8%	$26.23	161,794	05 Nov 2021	Direct	F1
holding	TVTX	Common Stock						19,500	05 Nov 2021	See footnote	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TVTX	Employee stock option (right to buy)	Options Exercise	$0	-10,000	-12%	$0.000000	70,000	05 Nov 2021	Common Stock	10,000	$16.23	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to an automatic trading plan adopted in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934.
F2	The shares are held in the name of the Aselage Family Trust.
F3	The stock option is fully vested and exercisable.